ساركوما إيوينج بعد الفشل في تحقيق استجابة الورم مع العلاج الكيميائي من الخط الثاني السابق

References

DOI: 10.1038/s41416-024-02868-4

• The most promising in terms of activity, toxicity and availability are the multi-targeted tyrosine kinase inhibitors.
• Pazopanib, cabozantinib and regorafenib have been reported to show single-agent activity.
• Oral etoposide is also frequently used to treat recurrent Ewing sarcoma.